Elissa S. Cote - Jun 23, 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Role: Chief Corp Development Officer
Signature: /s/ Cynthia Anderson, Attorney-in-Fact
Stock symbol: VTGN
Transactions as of: Jun 23, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/25/2025, 05:16 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cote Elissa S.	Chief Corp Development Officer	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO	/s/ Cynthia Anderson, Attorney-in-Fact	2025-06-25	0002069951

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VTGN	Stock Option (Right to Buy)	Award	$0	+150K		$0.00	150K	Jun 23, 2025	Common Stock	150K	$1.96	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the stock options vest on June 23, 2026 (the "Vesting Start Date") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date.
F2	The stock options were granted in connection with the Reporting Person's appointment as Chief Corporate Development Officer.